Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CTR20221796 | Registry Identifier | ChinaDrugTrial.org |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate. Participants will receive 1 injection of triptorelin pamoate 6-month formulation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Triptorelin pamoate 22.5 mg 6-month formulation | Experimental | All enrolled participants will receive one intramuscular (i.m.) injection of containing 22.5 mg 6-month formulation triptorelin pamoate on Day 1. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Triptorelin pamoate (embonate) salt | Drug | Triptorelin pamoate 22.5 mg (6-month formulation), i.m. injection, single dose on Day 1. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Who Achieved Castrate Levels of Serum Testosterone on Day 29 | Blood samples were collected to determine the serum testosterone concentrations using a validated, specific and sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Achievement of testosterone castration was defined as serum testosterone level <50 nanograms per deciliter (ng/dL) or 1.735 nanomoles/liter (nmol/L). Percentages are rounded off to the tenth decimal place. | Day 29 |
| Percentage of Participants Who Maintained the Castrate Levels From Week 8 to Week 24 | Blood samples were collected to determine the serum testosterone concentrations using a validated, specific and sensitive LC-MS/MS method. Maintenance of castration was defined as serum testosterone level <50 ng/dL or 1.735 nmol/L. | From Week 8 to Week 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment-Emergent Adverse Events of Local Tolerance | An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, or any other medically important event. TEAEs were AEs with start date on or after the date of study intervention administration and up to 24 weeks after date of first dose of treatment. Local tolerance was assessed 2 hours (+/-15 minutes) after the single injection of 6-month formulation triptorelin by examination of injection site for signs including but not limited to tenderness, erythema, swelling, hematoma, rash, pain, itching and induration. |
Not provided
Inclusion Criteria :
Exclusion Criteria :
Only Male is enrolled
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ipsen Medical, Director | Ipsen | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Affiliated Hospital of Hebei University | Baoding | China | ||||
| Beijing Hospital |
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.
Not provided
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.
Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/).
The study consisted of a 4-week screening period, single dose study intervention administration on Day 1 and an end of study on Day 169. A subset of participants had a more extensive sampling during the study to evaluate pharmacokinetics (PK) and pharmacodynamics (PD). A total of 195 participants were enrolled in the study.
This Phase IIIb, open-label, single arm study was conducted at 27 investigational sites in participants with locally advanced or metastatic prostate cancer.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Triptorelin Pamoate | Participants received a single dose of triptorelin pamoate 22.5 milligrams (mg) intramuscular (IM) injection on Day 1. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Mar 18, 2024 | Jul 22, 2025 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| From the first dose of study intervention (Day 1) up to end of study visit (Week 24), approximately 169 days |
| Percent Change From Baseline in Prostate Specific Antigen (PSA) at Weeks 12 and 24 | Blood samples were collected for the measurement of plasma PSA concentrations. Percent change in PSA was defined as the absolute value of difference between the PSA values at Week 12 and Week 24 and the baseline value divided by the baseline value. Baseline was defined as the last non-missing measurement taken prior to first study intervention administration. | Baseline (Day 1), Weeks 12 and 24 |
| Time to Maximum Observed Plasma Concentration (Tmax) of Triptorelin Pamoate | Blood samples were collected at specified timepoints for the assessment of tmax of triptorelin pamoate. The PK parameters were performed using non-compartmental analysis. | Pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 and 168 hours post-dose on Day 1, Days 15, 22, 29, 57, 85, 113, 141 and 169 |
| Maximum Observed Plasma Concentration (Cmax) of Triptorelin Pamoate | Blood samples were collected at specified timepoints for the assessment of Cmax of triptorelin pamoate. The PK parameters were performed using non-compartmental analysis. | Pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 and 168 hours post-dose on Day 1, Days 15, 22, 29, 57, 85, 113, 141 and 169 |
| Area Under the Plasma Concentration Time Curve From Time 0 to the Visit on Day 169 (AUC0-169) of Triptorelin Pamoate | Blood samples were collected at specified timepoints for the assessment of AUC0-169 of triptorelin pamoate. The PK parameters were performed using non-compartmental analysis. | Pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 and 168 hours post-dose on Day 1, Days 15, 22, 29, 57, 85, 113, 141 and 169 |
| Area Under the Plasma Concentration Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Triptorelin Pamoate | Blood samples were collected at specified timepoints for the assessment of AUClast of triptorelin pamoate. The PK parameters were performed using non-compartmental analysis. | Pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 and 168 hours post-dose on Day 1, Days 15, 22, 29, 57, 85, 113, 141 and 169 |
| Time to Maximum Observed Plasma Concentration of Testosterone | Blood samples were collected at specified timepoints for the assessment of tmax of testosterone. The PD parameters were performed using non-compartmental analysis. | Pre-dose on Day 1 and Days 2, 3, 5, 8, 15, 22, 29, 57, 85, 113, 141 and 169 |
| Maximum Observed Plasma Concentration of Testosterone | Blood samples were collected at specified timepoints for the assessment of Cmax of testosterone. The PD parameters were performed using non-compartmental analysis. | Pre-dose on Day 1 and Days 2, 3, 5, 8, 15, 22, 29, 57, 85, 113, 141 and 169 |
| Time to Castration of Testosterone | Blood samples were collected at specified timepoints for the assessment of tcast of testosterone. tcast was defined as time to reach serum testosterone level <50 ng/dL or 1.735 nmol/L. The PD parameters were performed using non-compartmental analysis. | Pre-dose on Day 1 and Days 2, 3, 5, 8, 15, 22, 29, 57, 85, 113, 141 and 169 |
| Plasma Concentrations of Triptorelin Pamoate | Blood samples were collected at specified timepoints for the assessment of plasma concentration of triptorelin pamoate. | Pre-dose on Day 1 and post-dose at Weeks 4, 8, 12, 16, 20 and 24 |
| Serum Concentrations of Testosterone | Blood samples were collected at specified timepoints for the assessment of serum concentration of testosterone. | Pre-dose on Day 1 and post-dose at Weeks 4, 8, 12, 16, 20 and 24 |
| Beijing |
| China |
| Peking University First Hospital | Beijing | China |
| Peking University People's Hospital | Beijing | China |
| Hunan Cancer Hospital | Changsha | China |
| West China Hospital of Sichuan University | Chengdu | China |
| Chongqing University Cancer Hospital | Chongqing | China |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing | China |
| Deyang People's Hospital | Deyang | China |
| Sun Yat-Sen University Cancer Center | Guangzhou | China |
| Guizhou Provincial People's Hospital | Guiyang | China |
| The Affiliated Hospital of Guizhou Medical University | Guiyang | China |
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou | China |
| Qilu Hospital of Shandong University | Jinan | China |
| Shandong Provincial Hospital | Jinan | China |
| Nanjing Drum Tower Hospital | Nanjing | China |
| Zhongda Hospital Southeast University | Nanjing | China |
| Ningbo First Hospital | Ningbo | China |
| Fudan University Shang Hai Cancer Center | Shanghai | China |
| Shanghai Fifth People's Hospital | Shanghai | China |
| Shanghai Tongji Hospital | Shanghai | China |
| Liaoning Cancer Hospital & Institute | Shenyang | China |
| The First Hospital of China Medical University | Shenyang | China |
| Peking University Shenzhen Hospital | Shenzhen | China |
| Suining Central Hospital | Suining | China |
| The Second Affiliated Hospital of Soochow University | Suzhou | China |
| Tianjin Cancer Hospital | Tianjin | China |
| The First Affiliated Hospital of Wenzhou Medical University | Wenzhou | China |
| The First Affiliated Hospital of Wannan Medical College | Wuhu | China |
| The Second Affiliated Hospital of Wannan Medical College | Wuhu | China |
| Wuxi People's Hospital | Wuxi | China |
| Northern Jiangsu People's Hospital | Yangzhou | China |
| Subei People's Hospital | Yangzhou | China |
| Yantai Yuhuangding Hospital | Yantai | China |
| Henan Cancer Hospital | Zhengzhou | China |
| Zigong First People's Hospital | Zigong | China |
| COMPLETED |
|
| NOT COMPLETED |
|
|
The safety set included all participants who received the single dose of study intervention.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Triptorelin Pamoate | Participants received a single dose of triptorelin pamoate 22.5 mg IM injection on Day 1. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants | No |
| |||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants | No |
| |||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants | No |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants Who Achieved Castrate Levels of Serum Testosterone on Day 29 | Blood samples were collected to determine the serum testosterone concentrations using a validated, specific and sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Achievement of testosterone castration was defined as serum testosterone level <50 nanograms per deciliter (ng/dL) or 1.735 nanomoles/liter (nmol/L). Percentages are rounded off to the tenth decimal place. | The full analysis set (FAS) included all treated participants who completed the study or were a treatment failure. | Posted | Number | 95% Confidence Interval | percentage of participants | Day 29 |
|
|
| |||||||||||||||||||||||||
| Primary | Percentage of Participants Who Maintained the Castrate Levels From Week 8 to Week 24 | Blood samples were collected to determine the serum testosterone concentrations using a validated, specific and sensitive LC-MS/MS method. Maintenance of castration was defined as serum testosterone level <50 ng/dL or 1.735 nmol/L. | The FAS included all treated participants who completed the study or were a treatment failure. | Posted | Number | 95% Confidence Interval | percentage of participants | From Week 8 to Week 24 |
|
| ||||||||||||||||||||||||||
| Secondary | Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment-Emergent Adverse Events of Local Tolerance | An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, or any other medically important event. TEAEs were AEs with start date on or after the date of study intervention administration and up to 24 weeks after date of first dose of treatment. Local tolerance was assessed 2 hours (+/-15 minutes) after the single injection of 6-month formulation triptorelin by examination of injection site for signs including but not limited to tenderness, erythema, swelling, hematoma, rash, pain, itching and induration. | The safety set included all participants who received the single dose of study intervention. | Posted | Count of Participants | Participants | No | From the first dose of study intervention (Day 1) up to end of study visit (Week 24), approximately 169 days |
| |||||||||||||||||||||||||||
| Secondary | Percent Change From Baseline in Prostate Specific Antigen (PSA) at Weeks 12 and 24 | Blood samples were collected for the measurement of plasma PSA concentrations. Percent change in PSA was defined as the absolute value of difference between the PSA values at Week 12 and Week 24 and the baseline value divided by the baseline value. Baseline was defined as the last non-missing measurement taken prior to first study intervention administration. | The FAS included all treated participants who completed the study or were a treatment failure. Only participants with data collected at specified timepoints are reported. | Posted | Mean | Standard Deviation | percent change | Baseline (Day 1), Weeks 12 and 24 |
|
| ||||||||||||||||||||||||||
| Secondary | Time to Maximum Observed Plasma Concentration (Tmax) of Triptorelin Pamoate | Blood samples were collected at specified timepoints for the assessment of tmax of triptorelin pamoate. The PK parameters were performed using non-compartmental analysis. | The rich PK analysis set included all participants in the rich PK/PD subset who received 1 dose of study intervention, had no major protocol deviations affecting the PK variables, and who had a sufficient number of plasma concentrations to estimate the main PK parameters (maximum observed plasma drug concentration [Cmax], tmax and area under the plasma concentration time curve [AUC]). | Posted | Median | Full Range | hour | Pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 and 168 hours post-dose on Day 1, Days 15, 22, 29, 57, 85, 113, 141 and 169 |
|
| ||||||||||||||||||||||||||
| Secondary | Maximum Observed Plasma Concentration (Cmax) of Triptorelin Pamoate | Blood samples were collected at specified timepoints for the assessment of Cmax of triptorelin pamoate. The PK parameters were performed using non-compartmental analysis. | The rich PK analysis set included all participants in the rich PK/PD subset who received 1 dose of study intervention, had no major protocol deviations affecting the PK variables, and who had a sufficient number of plasma concentrations to estimate the main PK parameters (Cmax, tmax and AUC). | Posted | Mean | Standard Deviation | ng/milliliter (mL) | Pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 and 168 hours post-dose on Day 1, Days 15, 22, 29, 57, 85, 113, 141 and 169 |
|
| ||||||||||||||||||||||||||
| Secondary | Area Under the Plasma Concentration Time Curve From Time 0 to the Visit on Day 169 (AUC0-169) of Triptorelin Pamoate | Blood samples were collected at specified timepoints for the assessment of AUC0-169 of triptorelin pamoate. The PK parameters were performed using non-compartmental analysis. | The rich PK analysis set included all participants in the rich PK/PD subset who received 1 dose of study intervention, had no major protocol deviations affecting the PK variables, and who had a sufficient number of plasma concentrations to estimate the main PK parameters (Cmax, tmax and AUC). Only those participants with data collected at specified timepoints are reported. | Posted | Mean | Standard Deviation | ng*day/mL | Pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 and 168 hours post-dose on Day 1, Days 15, 22, 29, 57, 85, 113, 141 and 169 |
|
| ||||||||||||||||||||||||||
| Secondary | Area Under the Plasma Concentration Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Triptorelin Pamoate | Blood samples were collected at specified timepoints for the assessment of AUClast of triptorelin pamoate. The PK parameters were performed using non-compartmental analysis. | The rich PK analysis set included all participants in the rich PK/PD subset who received 1 dose of study intervention, had no major protocol deviations affecting the PK variables, and who had a sufficient number of plasma concentrations to estimate the main PK parameters (Cmax, tmax and AUC). | Posted | Mean | Standard Deviation | ng*day/mL | Pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 and 168 hours post-dose on Day 1, Days 15, 22, 29, 57, 85, 113, 141 and 169 |
|
| ||||||||||||||||||||||||||
| Secondary | Time to Maximum Observed Plasma Concentration of Testosterone | Blood samples were collected at specified timepoints for the assessment of tmax of testosterone. The PD parameters were performed using non-compartmental analysis. | The rich PD analysis set included all participants in the rich PK/PD subset who had a sufficient number of PD (testosterone) measurements to estimate the main PD parameters (Cmax, tmax and time to castration [tcast]). | Posted | Median | Full Range | day | Pre-dose on Day 1 and Days 2, 3, 5, 8, 15, 22, 29, 57, 85, 113, 141 and 169 |
|
| ||||||||||||||||||||||||||
| Secondary | Maximum Observed Plasma Concentration of Testosterone | Blood samples were collected at specified timepoints for the assessment of Cmax of testosterone. The PD parameters were performed using non-compartmental analysis. | The rich PD analysis set included all participants in the rich PK/PD subset who had a sufficient number of PD (testosterone) measurements to estimate the main PD parameters (Cmax, tmax and tcast). | Posted | Mean | Standard Deviation | nmol/L | Pre-dose on Day 1 and Days 2, 3, 5, 8, 15, 22, 29, 57, 85, 113, 141 and 169 |
|
| ||||||||||||||||||||||||||
| Secondary | Time to Castration of Testosterone | Blood samples were collected at specified timepoints for the assessment of tcast of testosterone. tcast was defined as time to reach serum testosterone level <50 ng/dL or 1.735 nmol/L. The PD parameters were performed using non-compartmental analysis. | The rich PD analysis set included all participants in the rich PK/PD subset who had a sufficient number of PD (testosterone) measurements to estimate the main PD parameters (Cmax, tmax and tcast). | Posted | Median | Full Range | day | Pre-dose on Day 1 and Days 2, 3, 5, 8, 15, 22, 29, 57, 85, 113, 141 and 169 |
|
| ||||||||||||||||||||||||||
| Secondary | Plasma Concentrations of Triptorelin Pamoate | Blood samples were collected at specified timepoints for the assessment of plasma concentration of triptorelin pamoate. | The population PK analysis set included all participants who received 1 dose of triptorelin and who had at least 1 triptorelin plasma concentration and no major protocol deviations affecting PK variables. Only participants with data collected at specified timepoints are reported. | Posted | Mean | Standard Deviation | ng/mL | Pre-dose on Day 1 and post-dose at Weeks 4, 8, 12, 16, 20 and 24 |
|
| ||||||||||||||||||||||||||
| Secondary | Serum Concentrations of Testosterone | Blood samples were collected at specified timepoints for the assessment of serum concentration of testosterone. | The FAS included all treated participants who completed the study or were a treatment failure. Only participants with data collected at specified timepoints are reported. | Posted | Mean | Standard Deviation | nmol/L | Pre-dose on Day 1 and post-dose at Weeks 4, 8, 12, 16, 20 and 24 |
|
|
TEAEs are reported from the first dose of study intervention (Day 1) up to end of study visit (Week 24), approximately 169 days
The safety set included all participants who received the single dose of study intervention.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Triptorelin Pamoate | Participants received a single dose of triptorelin pamoate 22.5 mg IM injection on Day 1. | 0 | 195 | 8 | 195 | 90 | 195 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Abdominal hernia obstructive | Gastrointestinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Ileus | Gastrointestinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA 27.0 | Systematic Assessment |
| |
| Myelodysplastic syndrome | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 27.0 | Systematic Assessment |
| |
| Rectal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 27.0 | Systematic Assessment |
| |
| Cerebral infarction | Nervous system disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Lacunar infarction | Nervous system disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Skin oedema | Skin and subcutaneous tissue disorders | MedDRA 27.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA 27.0 | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA 27.0 | Systematic Assessment |
| |
| Alanine aminotransferase increased | Investigations | MedDRA 27.0 | Systematic Assessment |
| |
| Aspartate aminotransferase increased | Investigations | MedDRA 27.0 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Hyperhidrosis | Skin and subcutaneous tissue disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Hot flush | Vascular disorders | MedDRA 27.0 | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA 27.0 | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Medical Director | Ipsen | see email | clinical.trials@ipsen.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Sep 24, 2024 | Jul 22, 2025 | SAP_001.pdf |
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D017329 | Triptorelin Pamoate |
| D012492 | Salts |
| ID | Term |
|---|---|
| D007987 | Gonadotropin-Releasing Hormone |
| D010906 | Pituitary Hormone-Releasing Hormones |
| D007028 | Hypothalamic Hormones |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D009479 | Neuropeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D009842 | Oligopeptides |
| D009419 | Nerve Tissue Proteins |
| D011506 | Proteins |
| D007287 | Inorganic Chemicals |
Not provided
Not provided
| Unknown or Not Reported |
|
|
| Units | Counts |
|---|
| Participants |
|
|
|
|
|
|
|
|
|
|
|
|